ALV003: Clinical Trials

6 trials of ALV003, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 unknown. 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 26Completed 3, Terminated 2, Unknown 1

Follow ALV003: new trials by email Literature Review of ALV003 trials Research Report on ALV003

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Latiglutenase in T1D/CD Patients
Latiglutenase, Placebo - Celiac Disease
Phase 2TerminatedEntero Therapeutics132021-04-062024-08-05
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
Latiglutenase, Placebo - Celiac Disease
Phase 2TerminatedEntero Therapeutics832019-11-012024-08-05
Latiglutenase as a Treatment for Celiac Disease
Latiglutenase, Placebo - Celiac Disease
Phase 2CompletedImmunogenics, LLC792019-03-012021-12-15
Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
ALV003, placebo - Celiac Disease
Phase 2UnknownAlvine Pharmaceuticals Inc.5002013-08-012014-12-17
Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
ALV003, ALV003 placebo - Celiac Disease
Phase 2CompletedAlvine Pharmaceuticals Inc.612010-11-012012-08-06
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
ALV003, ALV003 placebo - Celiac Disease
Phase 2CompletedAlvine Pharmaceuticals Inc.742009-08-012012-08-06

Conditions studied

Celiac Disease (6)

Sponsors

Alvine Pharmaceuticals Inc. (3)  ·  Entero Therapeutics (2)  ·  Immunogenics, LLC (1)

Countries

United States (4)  ·  Finland (3)  ·  Canada (1)  ·  Ireland (1)  ·  Norway (1)  ·  United Kingdom (1)

Top investigators

Joseph Murray, MD (2)  ·  Daniel Adelman, MD (1)  ·  David Maahs, MD (1)

Results publications

PMID 24583059, PMID 27864127, PMID 28755266, PMID 35931103

NIH funding

R33AT009637 (1), R44DK121606 (1), U44AI134590 (1)